Snowball logo
logo
IMMN

Immunovia publ AB

IMMNOV ST
SEK 0.164+SEK 0.0018  (1.11%)
Estimate
EPS
-0.26
Beta
2.69
Growth
Revenue, YoY
169.06%
Net income, YoY
68.1%
FCF, YoY
14.25%
Forecast
EPS (FWD)
-0.04
About the company
Ticker
IMMNOV
ISIN
SE0006091997
Country
Sweden
Sector (GICS)
Healthcare
Immunovia AB (publ), a diagnostic company, develops and validates blood test for detecting pancreatic cancer in Sweden. It also focuses on the development and commercialization of blood-based testing to detect proteins and antibodies that indicate pancreatic cancer in an individual. Immunovia AB (publ) was incorporated in 2007 and is headquartered in Lund, Sweden.

Frequently asked questions

What sector does Immunovia publ AB (IMMNOV) operate in?

Immunovia publ AB belongs to the Healthcare sector and operates in the Diagnostics & Research industry.

What is Immunovia publ AB (IMMNOV) current stock price?

As of the latest data, Immunovia publ AB stock price is SEK 0.16, with a previous close of SEK 0.16. Immunovia publ AB gained SEK 0.00 in the last trading session, representing a 1.11% increase.

What is Immunovia publ AB (IMMNOV) current market capitalization?

Immunovia publ AB market cap is approximately 110.32 million.

What is Immunovia publ AB (IMMNOV) Earnings Per Share (EPS)?

The trailing EPS is -SEK 0.26, and the forward EPS is -SEK 0.04.

What is Immunovia publ AB (IMMNOV) EBITDA?

Immunovia publ AB EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) is -17.65 million.

Does Immunovia publ AB (IMMNOV) pay dividends?

No. Immunovia publ AB does not pay a dividend.

How did Immunovia publ AB (IMMNOV) perform in its most recent earnings report?

In the last report (March 31, 2026), Immunovia publ AB posted an EPS surprise of 25% and a revenue surprise of -62.6%.

What is Immunovia publ AB (IMMNOV) beta (volatility) score?

Immunovia publ AB has a beta of 2.690, indicating very high volatility compared to the market.